BioXcel Gets Nod For $125M Bankruptcy Sale To Teva
Published . Updated .
BioXcel Gets Nod For $125M Bankruptcy Sale To Teva Law360
Directly affected
- No company is named in this report.
Indirectly affected
- SPY SPDR S&P 500
The broad U.S. stock market
- TLT iShares 20+ Year Treasury Bond
Long-term U.S. government bonds
- QQQ Invesco QQQ
Large technology stocks
- GLD SPDR Gold Shares
Gold can move with the broad market
Price reaction, T-5 to T+3
BioXcel Gets Nod For $125M Bankruptcy Sale To Teva Law360
Source: Law360
How solid “BioXcel Gets Nod For $125M Bankruptcy Sale To Teva” looks
25 out of 100
“BioXcel Gets Nod For $125M Bankruptcy Sale To Teva” scores 25 out of 100. The score uses 2 sources.